Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-26

Contineum Therapeutics (CTNM)

CEO Carmine Stengone was paid $3,409,448 in fiscal year 2025, ↓ down 30.4% from fiscal year 2024 (SEC filing 0001628280-26-028881 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,409,448 ↓
Carmine Stengone total, FY2025
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Carmine Stengone (President and Chief Executive Officer), FY2025 total compensation $3,409,448 (base salary $655,620) [exec_comp, SEC accession 0001628280-26-028881, filed 2026-04-30]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

CTNM's next annual pay disclosure, estimated May 1, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Carmine Stengone$655,620$0$0$2,291,640$450,739$0$11,449$3,409,448
President and Chief Executive Officer
Timothy Watkins359,501225,0000984,556176,085018,1811,763,323
Chief Medical Officer and Head of Development
Peter Slover487,48700840,268238,869011,2791,577,903
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Carmine Stengone$3,409,448$4,900,039—↓ −1,490,591
Timothy Watkins1,763,323———
Peter Slover1,577,903———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Contineum Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper CTNM reports.

We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against CTNM
3 companies name CTNM as a compensation peer

Each company listed discloses CTNM in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CTNM in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Carmine StengoneCEO$3,409,448
Peter SloverCFO$1,577,903
Timothy WatkinsExecutive$1,763,323
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Diego MirallesDirector$254,156
Evert SchimmelpenninkChair of the Board$120,035
Lori M. Lyons-WilliamsIndependent Director$96,535
Olivia WareIndependent Director$94,035
Sarah BoyceIndependent Director$93,035
Todd BradyIndependent Director$102,535
Troy IgnelziIndependent Director$100,035
02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Peter SloverOption58,33415.76—
Peter SloverOption23,45010.81—
Carmine StengoneOption300,0009.79—
Carmine StengoneOption78,16410.81—
Carmine StengoneOption166,25015.76—
Peter SloverOption110,0009.79—
Timothy WatkinsOption122,7784.5—
05

Incentive-plan design — the Compensation Discussion & Analysis

The company's compensation program is designed to attract and retain talented executives by providing a competitive base salary and annual incentive bonus based on individual and corporate performance goals, including product development and clinical trial advancement. Long-term incentives are provided through stock options to align executive interests with stockholder value.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAlpine
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-26—————
20252025-06-26—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-26—a
20252025-06-26—b

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Diego MirallesNot independent$31,889$0$197,267—$25,000$254,156
Evert SchimmelpenninkIndependent · Board Chair · Compensation75,000045,035—0120,035
Todd BradyIndependent · Audit · Compensation (Chair)57,500045,035—0102,535
Troy IgnelziIndependent · Audit (Chair)55,000045,035—0100,035
Lori M. Lyons-WilliamsIndependent · Audit · Nominating and Corporate Governance51,500045,035—096,535
Olivia WareIndependent · Compensation · Nominating and Corporate Governance49,000045,035—094,035
Sarah BoyceIndependent · Nominating and Corporate Governance (Chair)48,000045,035—093,035
Carmine N. StengoneEmployee director—————0
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 8,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$367,889
Equity awards (grant-date value)$0
All other compensation$25,000
Total cost of the board$392,889

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Lori M. Lyons-Williams
10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Contineum Therapeutics2025Carmine Stengone$655,620$0$2,291,640$450,739$3,409,448

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Contineum Therapeutics in fiscal 2025?
As disclosed, Carmine Stengone (President and Chief Executive Officer) was the highest-paid executive at Contineum Therapeutics in fiscal 2025, with total compensation of $3,409,448.
How much does Contineum Therapeutics spend in total on board compensation for fiscal 2025?
As disclosed, Contineum Therapeutics reported total board compensation of $392,889 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Carmine StengoneDEF 14A2026-04-300001628280-26-028881Section “Executive Compensation”. As printed: 3,409,448. Filing ↗machine: span 271162–271171
2Section 01, Timothy WatkinsDEF 14A2026-04-300001628280-26-028881Section “Executive Compensation”. As printed: 1,763,323. Filing ↗machine: span 282198–282207
3Section 01, Peter SloverDEF 14A2026-04-300001628280-26-028881Section “Executive Compensation”. As printed: 1,577,903. Filing ↗machine: span 277701–277710
4Section 08, Diego MirallesDEF 14A2026-04-300001628280-26-028881Section “Director Compensation”. As printed: 254,156. Filing ↗machine: span 377777–378008
5Section 08, Evert SchimmelpenninkDEF 14A2026-04-300001628280-26-028881Section “Director Compensation”. As printed: 120,035. Filing ↗machine: span 374698–374929
6Section 08, Todd BradyDEF 14A2026-04-300001628280-26-028881Section “Director Compensation”. As printed: 102,535. Filing ↗machine: span 371797–372028
7Section 08, Troy IgnelziDEF 14A2026-04-300001628280-26-028881Section “Director Compensation”. As printed: 100,035. Filing ↗machine: span 373243–373474
8Section 08, Lori M. Lyons-WilliamsDEF 14A2026-04-300001628280-26-028881Section “Director Compensation”. As printed: 96,535. Filing ↗machine: span 379233–379463
9Section 08, Olivia WareDEF 14A2026-04-300001628280-26-028881Section “Director Compensation”. As printed: 94,035. Filing ↗machine: span 376143–376373
10Section 08, Sarah BoyceDEF 14A2026-04-300001628280-26-028881Section “Director Compensation”. As printed: 93,035. Filing ↗machine: span 370322–370584
11Section 08, Carmine N. StengoneDEF 14A2026-04-300001628280-26-028881Section “Director Compensation”. As printed: 0. Filing ↗
12Section 06, 2026 voteForm 8-K2026-06-260001628280-26-045804Item 5.07 · say-on-pay result. As reported: —. Filing ↗
13Section 06, 2025 voteForm 8-K2025-06-260001437749-25-021343Item 5.07 · say-on-pay result. As reported: —. Filing ↗
14Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
15Section 09b board cost (computed)Computed——Cash 367,889 + equity 0 + all other 25,000 = 392,889, summed across the director compensation table rows.machine: formula: Σ = 392,889
16Contineum Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-300001628280-26-028881CEO total compensation as printed in Contineum Therapeutics's own proxy. As printed: 3,409,448. Filing ↗machine: span 271162–271171